Related Experiment Videos
Toxicology of antisense therapeutics
Tracey L H Jason1, James Koropatnick, Randal W Berg
1Cancer Research Laboratories, London Regional Cancer Centre, London, Ontario, Canada N6A 4L6.
Toxicology and Applied Pharmacology
|November 3, 2004
Summary
Antisense oligonucleotides (ASOs) show promise for targeted gene silencing, with clinical trials demonstrating safety despite some toxicities. Future applications may involve combining ASOs with other therapeutics for enhanced cancer treatment.
Area of Science:
- Molecular Biology
- Pharmacology
- Genetics
Background:
- Antisense approaches leverage sequence specificity for targeted mRNA degradation or translation inhibition.
- Antisense oligonucleotides (ASOs) are a prevalent method for downregulating protein expression.
Purpose of the Study:
- To review the efficacy and safety of antisense oligonucleotides (ASOs) in therapeutic applications.
- To explore the potential of ASOs in cancer therapeutics and combination therapies.
Main Methods:
- Review of preclinical and clinical trial data for antisense oligonucleotide (ASO) therapies.
- Analysis of toxicities associated with ASO chemical structures.
Main Results:
- ASOs have successfully downregulated various target proteins.
- Clinical trials indicate ASOs are generally safe, with manageable toxicities like mild thrombocytopenia and hyperglycemia.
- Dose-limiting toxicities include hepatocellular degeneration, but are treatable.
Conclusions:
- ASOs can be safely administered to patients, with ongoing research into improved chemistries for enhanced efficacy and reduced toxicity.
- Combination therapy of ASOs with small molecule therapeutics presents a promising strategy for cancer treatment.